simvastatin + clopidogrel

Simvastatin + clopidogrel is a combination therapy consisting of two small molecule drugs commonly co-administered for the management of cardiovascular diseases. Simvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the enzyme responsible for cholesterol synthesis in the liver, thereby reducing total and LDL cholesterol and lowering cardiovascular risk. Clopidogrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 subtype of ADP receptor on platelets, preventing platelet aggregation and reducing the risk of thrombotic events such as myocardial infarction or stroke. This combination is often used in patients with ischemic heart disease or those undergoing percutaneous coronary intervention to reduce both lipid levels and platelet activity. Some studies suggest simvastatin may attenuate clopidogrel’s antiplatelet effect due to shared metabolism via CYP3A4, but clinical evidence does not consistently show significant adverse outcomes from their combined use[1][3][4].